Investigación / Grupos de investigación

Grupo  2

Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Publicaciones (884)

  • Lonardi, S; Lugowska, I; O'Donnell, A; Jackson, C; Latten-Jansen, LM; North, R; Bahleda, R; Garrido, M; Santoro, A; Chacon, MR; Li, LH; Joseph, D; Vezina, HE; Aras, U; Bennett, B; Perumal, D; Gurm, B; Ng, WT; Harvey, RD; Trigo, J; Calvo, A.

    Pharmacokinetics and safety of subcutaneous nivolumab: results from the phase I/II CheckMate 8KX study

    Journal for ImmunoTherapy of Cancer. 2025; 13(10): [doi:10.1136/jitc-2025-011918]

  • Cho, BC; Ahn, MJ; Nishio, M; Murakami, H; Wan-Kim, D; Kim, SW; Karam, SD; Estival, A; Lin, CC; Trigo, JM; Alvarez, R; Wang, CL; Xie, MC; Iyer, S; Armstrong, J; Chugh, P; Jiang, HY; Bauman, JE.

    Durvalumab With or Without Tremelimumab in Combination With Chemoradiotherapy in Patients With Limited-Stage SCLC: Results from the Phase 1 CLOVER Study

    Jto Clinical And Research Reports. 2025; 6(10): [doi:10.1016/j.jtocrr.2025.100884]

  • Lobato-Delgado, B; Ruiz, M; Font, C; Pachón, V; Castellón, V; Martinez-Marin, V; Salgado, M; Martinez, E; Calzas, J; Ortega, L; Ruperez, A; Pujol, O; Soria, JM; Muñoz, A.

    Cancer-associated venous thromboembolism and its impact on survival in the ONCOTHROMB12-01 cohort study

    IJC HEART & VASCULATURE. 2025; 60: [doi:10.1016/j.ijcha.2025.101754]

  • Soto-Alsar, J; Revuelta-Herrero, JL; Villanueva-Bueno, C; Cobos-Lama, C; Cañete-Muñoz, MA; Muñoz-Martin, A; Garcia-Alfonso, P; Soto-Alvarez, J.

    Budget impact analysis of new drugs in oncology and haematology: Principles and practice

    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2025; : [doi:10.1002/bcp.70303]

  • Vaz-Salgado, MA; Valverde-Morales, C; Alvarez, R; Asencio, JM; Collado, E; de Alava, E; Beveridge, RD; Gómez-Mateo, MC; Alegria, IG; Marquina, G; Broto, JM; Martínez-Trufero, J; Narváez, JA; Redondo, A; Sebio, A; Verges, R; Viñals, JM; del Muro, XG.

    Diagnosis and Therapy of Soft Tissue Sarcomas: Spanish Group for Research in Sarcomas (GEIS) Guidelines

    Cancers. 2025; 17(19): [doi:10.3390/cancers17193158]

  • Fasching, PA; Stroyakovskiy, D; Yardley, DA; Huang, CS; Crown, J; Bardia, A; Chia, S; Im, SA; Martin, M; Xu, BH; Loi, S; Barrios, C; Untch, M; Moroose, R; Visco, F; Hortobagyi, GN; Slamon, DJ; Fresco, R; Zarate, JP; Li, Z; Waters, S; Hurvitz, SA.

    Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial

    JAMA Oncology. 2025; : Nº de citas: 1 [doi:10.1001/jamaoncol.2025.3700]

  • Ramirez, SP; Fidalgo, AP; Ginesta, MPB; Ferre, AD; Madrid, LF; Martinez, AG; Montosa, FG; Madariaga, A; Gómez, TM; Gil-Martin, M.

    SEOM-GEICO clinical guidelines on endometrial cancer (2025)

    CLINICAL & TRANSLATIONAL ONCOLOGY. 2025; 27(12): 4368-4380 [doi:10.1007/s12094-025-04046-1]

  • Mezquita, L; Vicente-Herrero, MT; Cruz, P; de la Torre, MVRI; Hidalgo-Coloma, J; Garcia, LC; Gallego, O; Calvo, A; Martinez, K; Perez-Altozano, J; Molina, R; Garcia-Pardo, M; Gutierrez-Sainz, L; Moreno-Atahonero, E; Ore-Arce, M; Serrano, C; Terradillos-Garcia, MJ; Valero, MR; Reinoso-Barbero, L; Rodriguez, CA; Calvo-Cerrada, B.

    SEOM-AEEMT consensus on occupational cancer and cancer-associated disability

    CLINICAL & TRANSLATIONAL ONCOLOGY. 2025; : [doi:10.1007/s12094-025-04037-2]

  • Cánovas, MS; Robles, JL; Verdejo, FJG; Lavin, DC; Olivares, H; Fernández, AG; Salvans, EC; Verduguez, TQ; Coloma, CS; Garay, DF; Cumplido, JD; Pérez, AIF; Bagué, AC; Muñoz, FJT; López, RG; Marin, AM; Martín, AJM.

    PARP inhibitors-associated thrombosis in patients with ovarian cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group

    CLINICAL & TRANSLATIONAL ONCOLOGY. 2025; : [doi:10.1007/s12094-025-04048-z]

  • Rojo, F; Taylor, CR; Barrios, C; Torrecillas, L; Ruiz-Borrego, M; Perez-Buira, S; Bines, J; Guerrero-Zotano, A; Garcia-Saenz, JA; Torres, R; de la Haba-rodriguez, J; Ayala, F; Gomez, H; Llombart, A; de la Borbolla, MR; Baena-Cañada, JM; Barnadas, A; Calvo, L; Herranz, J; Rincon, R; Caballero, R; Bermejo, B; Ray, PS; Martin, M.

    FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial

    CLINICAL CANCER RESEARCH. 2025; 31(17): 3715-3724 [doi:10.1158/1078-0432.CCR-25-0338]

  • Garcia-Carbonero, R; Elez, E; García-Alfonso, P; Gracían, AC; Lopez, RL; Jimenez-Fonseca, P; Miron, MLL; Dasari, A; Lonardi, S; Zhu, H; Chen, L; Yang, Z; Schelman, WR; Tabernero, J.

    Analysis of fruquintinib in patients with metastatic colorectal cancer who were enrolled in Spain: results from the global FRESCO-2 study

    Esmo Gastrointestinal Oncology. 2025; 9: 100205-100205 Nº de citas: 1 [doi:10.1016/j.esmogo.2025.100205]

  • Hoffman-Censits, J; Tsiatas, M; Chang, PMH; Kim, M; Antonuzzo, L; Shin, SJ; Gakis, G; Blais, N; Kim, SH; Smith, A; Arija, JAA; Su, YL; Zagouri, F; Maruzzo, M; Tournigand, C; Forget, F; Schneider, A; Tyroller, K; Jacob, N; Grivas, P; Valderrama, BP.

    Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysis

    ANNALS OF ONCOLOGY. 2025; 36(9): [doi:10.1016/j.annonc.2025.05.010]

  • Kyriazoglou, A; Zajac, A; Valverde, C; Czarnecka, AM; Blonski, P; Romagosa, C; Seliga, KA; Koulouridi, A; Mala, A; Wagrodzki, M; Silva, TM; Witczak, M; Lugowska, I; Rosinska, M; Alvarez, R; Aguirre, M; Tysarowski, A; Kokkali, S; Georgoulias, V; Serrano, C; Rutkowski, P; Boukovinas, I.

    Exploring the impact of NGS on diagnostics and treatment of sarcoma: insights from real-world data across multiple institutions in Europe

    Esmo Open. 2025; 10(9): [doi:10.1016/j.esmoop.2025.105577]

  • Blasco, A; López-Tarruella, S; Urruticoechea, A; Carrasco, E; Spera, G; Martin, M; Bermejo, B; Chap, L; Ruiz-Borrego, M; Crown, J; Garcia-Saenz, JA; Chan, A; Guerrero-Zotano, A; Semiglazov, V; Calvo, L; Pienkowski, T; Herranz, J; Slamon, D.

    Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials

    ONCOLOGIST. 2025; 30(9): [doi:10.1093/oncolo/oyaf263]

  • Martelli, V; Vidal, J; Gibert, J; Fernández-Rodriguez, MC; Linares, J; Garcia-Alfonso, P; Páez, D; Alonso, V; Gomez-España, MA; Guix, M; Santos, C; Duran, G; Élez, E; Garcia-Carbonero, R; Ferreiro, R; Pineda, E; Sastre, J; Cano, MT; Manzano, JL; Losa, F; Aranda, E; Rivera, F; Sibilio, A; Toledo, R; Tabernero, J; Salazar, R; Bellosillo, B; Montagut, C.

    Clinical validation of liquid biopsy-RECIST (LB-RECIST) in metastatic colorectal cancer (mCRC) patients: findings from the PLATFORM-B study

    Esmo Open. 2025; 10(9): [doi:10.1016/j.esmoop.2025.105760]

  • Márquez-Rodas, I; Dutriaux, C; Saiag, P; Merino, LD; Alvarez, EC; Robert, C; Rodríguez-Moreno, JF; Arance, A; Cerezuela-Fuentes, P; Montaudié, H; Sanmamed, MF; González-Cao, M; Charles, J; Criado, MPL; Berrocal, A; De Miguel, E; Funck-Brentano, E; Prey, S; de la Gala, MCA; Melero, I; Avilés-Izquierdo, JA; Roman, R; Garcia-Pelaez, B; Rodriguez, S; Trnkova, ZJ; Quintero, M; Maciá, S; Chaney, MF; Dalle, S.

    BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203

    JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(25): [doi:10.1200/JCO-24-02595]

  • Pérez-Bilbao, T; López-Tarruella, S; Alonso-Dueñas, M; San Juan, AF; Ferreres-García, K; Martín, M; Peinado, AB; Rojo, F.

    Effects of presurgical HIIT in hormone receptor-positive, HER 2-negative breast cancer cases: Two case reports from the GEICAM EFiK study

    Physiological Reports. 2025; 13(16): [doi:10.14814/phy2.70511]

  • Gonzalez-Cao, M; Berciano-Guerrero, MA; Muñoz-Couselo, E; Manzano, JL; Cerezuela-Fuentes, P; Crespo, G; Soria, A; de Miguel, PA; Sanz, LG; de la Rosa, CA; Castaño, AG; Puértolas, T; Espinosa, E; Medina, J; Bellido, L; Berrocal, A; Majem, M; Castro, RL; Fernandez, LA; Garcia, F; de la Borbolla, MR; Algarra, SM; Márquez-Rodas, I.

    Poor efficacy of anti PD-1 antibody based immunotherapy in patients with acral melanoma: results from the Spanish Melanoma Group (GEM) registry

    CLINICAL & TRANSLATIONAL ONCOLOGY. 2025; : [doi:10.1007/s12094-025-04018-5]